Updated Nov. 28, 2011 at 6:30 a.m.
Treximet
Research Triangle Park, N.C. — Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan. Copyright 2013 MedCity. All rights reserved.
Pozen sells royalty rights to migraine drug for $75M
Post a comment
Print this blog postE-mail blog post
Share
Treximet
Research Triangle Park, N.C. — Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan. Copyright 2013 MedCity. All rights reserved.
Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy - Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle
- ChannelAdvisor seeks $80M, sets share target price for IPO